Advertisement

Drugs

, Volume 47, Issue 2, pp 207–222 | Cite as

Long- Versus Short-Acting β2-Agonists

Implications for Drug Therapy
  • Louis-Philippe Boulet
Leading Article

Keywords

Asthma Salbutamol Salmeterol Asthma Control Terbutaline 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Ahlquist RP. A study of adrenotropic receptors. American Journal of Physiology 153: 586–600, 1948PubMedGoogle Scholar
  2. American Academy of Allergy and Immunology Executive Committee. Position statement: inhaled β2-adrenergic agonists in asthma. Journal of Allergy and Clinical Immunology 91: 1234–1237, 1993CrossRefGoogle Scholar
  3. Anderson GP. Pharmacology of formoterol: an innovative bronchodilator. Agents and Actions 34 (Suppl.): 97–115, 1991CrossRefPubMedGoogle Scholar
  4. Anderson GP. Long acting inhaled beta-adrenoceptor agonists: the comparative pharmacology of formoterol and salmeterol. In New drugs in allergy and asthma, pp. 253–269, Birkhaμser Verlag, Basel, 1993CrossRefGoogle Scholar
  5. Anderson SD, Rodwell LT, Du Toit J, Young IH. Duration of protection by inhaled salmeterol in exercise-induced asthma. Chest 100: 1254–1260, 1991CrossRefPubMedGoogle Scholar
  6. Arvidsson P, Larsson S, Löfdahl CG, Melander B, Svedmyr N, et al. Inhaled formeterol during one year in asthma: a comparison with salbutamol. European Respiratory Journal 4: 1168–1173, 1991PubMedGoogle Scholar
  7. Arvidsson P, Larsson S, Lofdahl CG, Melander B, Wahlander L, et al. Formoterol, a new long-acting bronchodilator for inhalation. European Respiratory Journal 2: 325–330, 1989PubMedGoogle Scholar
  8. Ball DI, Brittain RT, Coleman RA, Denyer LH, Jack D, et al. Salmeterol, a novel, long-acting beta 2-adrenoceptor agonist: characterization of pharmacological activity in vitro and in vivo. British Journal of Pharmacology 104: 665–671, 1991CrossRefPubMedGoogle Scholar
  9. Bandouvakis J, Cartier A, Roberts R, Ryan G, Hargreave FE. The effect of ipratropium and fenoterol on methacholine and histamineinduced bronchoconstriction. British Journal of Diseases of the Chest 75: 295–305, 1981CrossRefPubMedGoogle Scholar
  10. Barnes PJ. New concepts in the pathogenesis of bronchial hyperresponsiveness and asthma. Journal of Allergy and Clinical Immunology 83: 1013–1026, 1989CrossRefPubMedGoogle Scholar
  11. Barnes PJ. New drugs for asthma. European Respiratory Journal 5: 1126–1136, 1992aPubMedGoogle Scholar
  12. Barnes PJ, Chung KF. Questions about inhaled β2-agonists in asthma. Trends in Pharmacological Sciences 13: 20–23, 1992CrossRefPubMedGoogle Scholar
  13. Beach JR, Young CL, Harkawat R, Gardiner PV, Avery AJ, et al. Effect on airway responsiveness of six weeks treatment with salmeterol. Pulmonary Pharmacology 6: 155–157, 1993CrossRefPubMedGoogle Scholar
  14. Beach JR, Young CL, Stenton SC, Avery AJ, Walters EH, et al. A comparison of the speeds of action of salmeterol and salbutamol in reversing methacholine-induced bronchoconstriction. Pulmonary Pharmacology 5: 133–135, 1992CrossRefPubMedGoogle Scholar
  15. Becker AB, Simons FE. Formoterol, a new long-acting selective beta 2-adrenergic receptor agonist: double-blind comparison with salbutamol and placebo in children with asthma. Journal of Allergy and Clinical Immunology 84: 891–895, 1989CrossRefPubMedGoogle Scholar
  16. Becker AB, Simons FE. Formoterol, a new long-acting selective beta 2-agonist, decreases airway responsiveness in children with asthma. Lung 168: 99–102, 1990CrossRefPubMedGoogle Scholar
  17. Bel EH, Zwinderman AH, Timmers MC, Dijkman JH, Sterk PJ. The protective effect of a β-2 agonist against excessive airway narrowing in response to bronchoconstrictor stimuli in asthma and chronic obstructive lung disease. Thorax 46: 9–14, 1991CrossRefPubMedGoogle Scholar
  18. Bennati D, Piacentini GL, Reroni DG, Sette L, Esty R, et al. Changes in bronchial reactivity in asthmatic children after treatment with beclomethasone alone or in association with salbutamol. Journal of Asthma 26: 359–364, 1989CrossRefPubMedGoogle Scholar
  19. Beswick KBJ, Pover GM, Sampson S. Long-term regularly inhaled salbutamol. Current Medical Research and Opinion 10: 228–234, 1986CrossRefPubMedGoogle Scholar
  20. Blaiss MS. New pharmacologic agents in the treatment of asthma. Allergy Proceedings 14: 17–21, 1993CrossRefPubMedGoogle Scholar
  21. Boner A. Salmeterol: long-term studies in children. European Respiratory Journal 5 (Suppl. 15): A318, 1992Google Scholar
  22. Boulet LP, Turcotte H, Tennina S. Comparative efficacy of salbutamol, ipratropium and cromoglycate in the prevention of the bronchospasm induced by exercise and hyperosmolar challenges. Journal of Allergy and Clinical Immunology 83: 882–887, 1989CrossRefPubMedGoogle Scholar
  23. Boyd G, Anderson K, Carter R. Placebo controlled comparison of the bronchodilator performance of salmeterol and salbutamol over 12 hours. Thorax 45: A340, 1990Google Scholar
  24. Bremner P, Woodma K, Burgess C, Crane J, Purdie G, et al. A comparison of the cardiovascular and metabolic effects of formoterol, salbutamol and fenoterol. European Respiratory Journal 2: 204–210, 1993Google Scholar
  25. British Thoracic Society, et al. Guidelines for the management of asthma: a summary. British Medical Journal 306: 776–782, 1993CrossRefGoogle Scholar
  26. Britton J. Tolerance to beta-agonists in asthma therapy. Lancet 342: 818–819, 1993CrossRefPubMedGoogle Scholar
  27. Britton JR, Hanley SP, Garrett HV, Hadfield JW, Tattersfield AE. Dose related effects of salbutamol and ipratropium bromide on airway calibre and reactivity in subjects with asthma. Thorax 43: 300–305, 1988CrossRefPubMedGoogle Scholar
  28. Britton MG, Earnshaw JS, Palmer JB. A twelve month comparison of salmeterol with salbutamol in asthmatic patients: European Study Group. European Respiratory Journal 5: 1062–1067, 1992PubMedGoogle Scholar
  29. Brogden RN, Faulds D. Salmeterol xinafoate: a review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease. Drugs 42: 895–912, 1991CrossRefPubMedGoogle Scholar
  30. Buist AS, Burney PGI, Feinstein AR, Horwitz RI, Lames SF, et al. Feneterol and fatal asthma. Correspondence. Lancet 1: 1071–1072, 1989Google Scholar
  31. Burrows B, Lebowitz MD. The β-agonist dilemma. New England Journal of Medicine 326: 560–561, 1992CrossRefPubMedGoogle Scholar
  32. Butcher PR, Vardey CJ, Johnson M. Salmeterol: a potent and longacting inhibitor of inflammatory mediator release from human lung. British Journal of Pharmacology 104: 672–676, 1991CrossRefGoogle Scholar
  33. Campos-Gongora H, Wisniewski AFZ, Tattersfield AE. A singledose comparison of inhaled albuterol and two formulations of salmeterol on airway reactivity in asthmatic subjects. American Review of Respiratory Disease 144: 626–629, 1991CrossRefGoogle Scholar
  34. Castle W, Fuller R, Hall J, Palmer J. Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment. British Medical Journal 306: 1034–1037, 1993CrossRefPubMedGoogle Scholar
  35. Chetta A, Del Donno M, Maiocchi G, Pisi G, Moretti D, et al. Prolonged bronchodilating effect of formoterol versus procaterol in bronchial asthma. Annals of Allergy 70: 171–174, 1993PubMedGoogle Scholar
  36. Cheung D, Timmers MC, Zwinderman AH, Bel EH, Dijkman JH, et al. Long-term effects of a long-acting beta 2-adrenoreceptor agonist, salmeterol, on airway hyperresponsiveness in patients with mild asthma. New England Journal of Medicine 327: 1198–1203, 1992CrossRefPubMedGoogle Scholar
  37. Clark CE, Ferguson AD, Siddon JA. Respiratory arrests in young asthmatics on salmeterol. Respiratory Medicine 87: 227–228, 1993CrossRefPubMedGoogle Scholar
  38. Clauzel AM. Characteristics of bronchodilating activity of formoterol. Lung 168 (Suppl.): 71–75, 1990CrossRefPubMedGoogle Scholar
  39. Connolly ME, Jenne JW, Hui KK, Borst SE. Beta-adrenergic tachyphyIaxis (desensitization) and functional antagonism. In Jenne & Murphy (Eds) Drug therapy for asthma: research and clinical practice, pp. 259–296, Marcel Dekker, New York, 1987Google Scholar
  40. Costain D, Harrison BDW, Holgate S, Hopkins AP, Partridge MR, et al. Guidelines for management of asthma in adults: I. chronic persistent asthma. British Medical Journal 301: 651–653, 1990CrossRefGoogle Scholar
  41. Crane J, Burgess C, Beasley R. Cardiovascular and hypokalemic effects of inhaled salbutamol, fenoterol, and isoprenaline. Thorax 44: 136–140, 1989bCrossRefPubMedGoogle Scholar
  42. Crane J, Pearce N, Flatt A, Burgess C, Jackson R, et al. Prescribed fenoterol and death from asthma in New Zealand 1981-83: case control study. Lancet 1: 917–922, 1989aCrossRefPubMedGoogle Scholar
  43. Dahl R, Earnshaw JS, Palmer JBD. Salmeterol: a four week study of a long-acting beta-adrenoreceptor agonist for the treatment of reversible airway disease. European Respiratory Journal 4: 1178–1184, 1991aPubMedGoogle Scholar
  44. Dahl R, Pedersen B. The influence of inhaled salmeterol on bronchial inflammation. A bronchoalveolar lavage study in patients with bronchial asthma. European Respiratory Journal 3 (Suppl. 10): 226S, 1990Google Scholar
  45. Dahl R, Pedersen B, Venge P. Bronchoalveolar lavage studies. European Respiratory Review 4: 272–275, 1991bGoogle Scholar
  46. Derom EY, Pauwels RA. Time course of bronchodilating effect of inhaled formoterol, a potent and long acting sympathomimetic. Thorax 47: 30–33, 1992CrossRefPubMedGoogle Scholar
  47. Derom EY, Pauwels RA, Van Der Straeten ME. The effect of inhaled salmeterol on methacholine responsiveness in subjects with asthma up to 12 hours. Journal of Allergy and Clinical Immunology 89: 811–815, 1992CrossRefPubMedGoogle Scholar
  48. Douglas NJ, Fitzpatrick ME Effects of salmeterol on nocturnal asthma. European Respiratory Review 4: 293–296, 1991Google Scholar
  49. Ernst P, Habbick B, Suissa S, Hemmerlgarn B, Cockcroft DW, et al. Is the association between inhaled beta-agonist use and life-threatening asthma because of confounding by severity?. American Review of Respiratory Disease 148: 75–79, 1993PubMedGoogle Scholar
  50. Ernst P, Spitzer W, Suissa S, Cockcroft DW, Habbick B, et al. Risk of fatal and near-fatal asthma in relation to inhaled corticosteroid use. Journal of the American Medical Association 268: 3462–3464, 1992CrossRefPubMedGoogle Scholar
  51. Faulds D, Hollingshead LM, Goa KL. Formoterol: a review of its pharmacological properties and therapeutic efficacy in reversible obstructive airways disease. Drugs 42: 115–137, 1991CrossRefPubMedGoogle Scholar
  52. Faurschou P. Salmeterol and salbutamol: long-term efficacy and safety. European Respiratory Journal 5 (Suppl. 15): A317, 1992Google Scholar
  53. Ferguson H, Thomas KE, Davies RJ. Comparison of single dose formoterol and terbutaline on the immediate asthmatic response to allergen provocation testing. Clinical and Experimental Allergy 19: A118, 1989Google Scholar
  54. Fitzpatrick MF, Mackay T, Driver H, Douglas NJ. Salmeterol in nocturnal asthma: a double blind, placebo controlled trial of a long acting inhaled beta 2 agonist. British Medical Journal 301: 1365–1368, 1990CrossRefPubMedGoogle Scholar
  55. Flatt A, Crane J, Purdie G, Kwong T, Beasley R, et al. The cardiovascular effects of beta adrenergic agonist drugs administered by nebulisation. Postgraduate Medicine 66: 98–101, 1990CrossRefGoogle Scholar
  56. Foucard T, Lonnerholm G. A study with cumulative doses of formoterol in children with asthma. European Respiratory Journal 4: 1174–1177, 1991PubMedGoogle Scholar
  57. Gongora HC, Wisniewski AF, Tattersfield AE. A single-dose comparison of inhaled albuterol and two formulations of salmeterol on airway reactivity in asthmatic subjects. American Reviews of Respiratory Disease 144: 626–629, 1991CrossRefGoogle Scholar
  58. Graff-Lonnevig V, Browaldh L. Twelve hours’ bronchodilating effect of inhaled formoterol in children with asthma: a double-blind cross-over study versus salbutamol. Clinical and Experimental Allergy 20: 429–432, 1990CrossRefPubMedGoogle Scholar
  59. Grainger J, Woodman K, Pearce N, Crane J, Burgess C, et al. Prescribed fenoterol and death from asthma in New Zealand, 1981–1987: a further case control study. Thorax 46: 105–111, 1991CrossRefPubMedGoogle Scholar
  60. Gratziou C, Roberts JA, Bradding P, Holgate ST, Howarth PH. The influence of long-acting β2-agonist salmeterol xinafoate. American Review of Respiratory Disease 145: A67, 1992Google Scholar
  61. Green CP, Price JF. Prevention of exercise induced asthma by inhaled salmeterol xinafoate. Archives of Diseases of the Child 67: 1014–1017, 1992CrossRefGoogle Scholar
  62. Guerin JC, Brambilla C, Godard P, De Muizon H, Aubert B, et al. Prolonged effect against exercise-induced bronchospasm: salmeterol versus sodium cromoglycate. Revue des Maladies Respiratoires 9 (Suppl. IP): R27–R30, 1992PubMedGoogle Scholar
  63. Haahtela T, Järvinen M, Kava T, Kiviranta K, Koskinen S, et al. Comparison of a β2 agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. New England Journal of Medicine 325: 388–392, 1991CrossRefPubMedGoogle Scholar
  64. Hargreave FE, Dolovich J, Newhouse MT (Eds). The assessment of asthma: a conference report. Journal of Allergy and Clinical Immunology 85: 1098–1111, 1990CrossRefPubMedGoogle Scholar
  65. Harvey JE, Tattersfield AE. Airway response to salbutamol: effect of regular salbutamol inhalations in normal, atopic, and asthmatic subjects. Thorax 37: 280–287, 1982CrossRefPubMedGoogle Scholar
  66. Hedenstrom H, Wegener T, Boman G, Wahlander L, Melander B. Effect of inhaled formoterol versus terbutaline on respiratory function in moderate bronchial asthma. Allergy 47: 158–163, 1992CrossRefPubMedGoogle Scholar
  67. Hekking PR, Maesen F, Greefhorst A, Prins J, Tan Y, Zweers R Long-term efficacy of formoterol compared to salbutamol. Lung 168 (Suppl.): 76–82, 1990CrossRefPubMedGoogle Scholar
  68. Henriksen JM, Agertoft L, Pedersen S. Protective effect and duration of action of inhaled formoterol and salbutamol on exercise-induced asthma in children. Journal of Allergy and Clinical Immunology 89: 1176–1182, 1992CrossRefPubMedGoogle Scholar
  69. Inman WHW, Adelstein AM. Rise and fall of asthma mortality in England and Wales in relation to use of pressurised aerosols. Lancet 2: 279–285, 1969CrossRefPubMedGoogle Scholar
  70. International Consensus Report. Diagnosis and treatment of asthma. Clinical and Experimental Allergy 89 (Suppl. 1): 1–72, 1992Google Scholar
  71. Jeppsson AB, Löfdahl CG, Waldeck B, Widmark E. On the predictive value of experiments in vitro in the evaluation of the effect and duration of bronchodilator drugs for local administration. Pulmonary Pharmacology 2: 81–85, 1989CrossRefPubMedGoogle Scholar
  72. Johnson M. The pharmacology of salmeterol. Lung 168 (Suppl.) 115–119, 1990CrossRefPubMedGoogle Scholar
  73. Johnson M. Salmeterol: a novel drug for the treatment of asthma. Agents and Actions 34 (Suppl.): 79–95, 1991aPubMedGoogle Scholar
  74. Johnson M. The preclinical pharmacology of salmeterol: bronchodilator effects. European Respiratory Review 4: 253–256, 1991bGoogle Scholar
  75. Kelly HW. New β2-adrenergic agonists aerosols. Clinical Pharmacy 4: 393–403, 1985PubMedGoogle Scholar
  76. Kemp JP, Bierman CW. Cocchetto DM. Dose-response study of inhaled salmeterol in asthmatic patients with 24-hour spirometry and Holter monitoring. Annals of Allergy 70: 316–322, 1993PubMedGoogle Scholar
  77. Kerrebijn KF, van Essen-Zandvliet EEM, Neijens HJ. Effect of long-term treatment with inhaled corticosteroids and β-agonists on the bronchial responsiveness in children with asthma. Journal of Allergy and Clinical Immunology 79: 653–659, 1987CrossRefPubMedGoogle Scholar
  78. Kesten S, Chapman KR, Broder I, Cartier A, Hyland RH, et al. A three-month comparison of twice daily inhaled formoterol versus four times daily inhaled albuterol in the management of stable asthma. American Review of Respiratory Disease 144: 622–625, 1991CrossRefPubMedGoogle Scholar
  79. Kesten S, Chapman KR, Broder I, Cartier A, Hyland RH, et al. Sustained improvement in asthma with long-term use of formoterol fumerate. Annals of Allergy 69: 415–420, 1992PubMedGoogle Scholar
  80. Kraan J, Koeter GH, van der Mark ThW, Sluiter HJ, de Vries K. Changes in bronchial hyperreactivity induced by 4 weeks of treatment with antiasthmatic drugs in patients with allergic asthma: a comparison between budesonide and terbutaline. Journal of Allergy and Clinical Immunology 76: 628–636, 1985CrossRefPubMedGoogle Scholar
  81. Kuitert LM. β-Agonists in asthma-state of the art: report on a Royal Society of Medicine seminar. Thorax 47: 568–569, 1992CrossRefPubMedGoogle Scholar
  82. Laitinen LA, Laitinen A, Haahtela T. A comparative study of the effects of an inhaled corticosteroids, budesonide, and of a β2 agonist, terbutaline, on airway inflammation in newly-diagnosed asthma. Journal of Allergy and Clinical Immunology 90: 32–42, 1992CrossRefPubMedGoogle Scholar
  83. Lands AM, Arnold A, McAuliff JP, Luduena P, Brown TG. Differentiation of receptor systems activated by sympathomimetic amines. Nature 214: 597–598, 1967CrossRefPubMedGoogle Scholar
  84. Larsson S. Long-term studies on long-acting sympathomimetics. Lung 168 (Suppl.): 22–24, 1990CrossRefPubMedGoogle Scholar
  85. Lemanske RF, Joad J. Beta-2 receptor agonists in asthma: a comparison. Journal of Asthma 27: 101–109, 1990CrossRefPubMedGoogle Scholar
  86. Leuenberger P, Gebre-Michel I. Preventative effect of formoterol aerosol in methacholine-induced bronchoconstriction. In Davies (Ed.) Formoterol in asthma — clinical profile of a new long-acting inhaled β2-agonist, pp. 32–37, Hans Huber Publishers, Toronto, 1988Google Scholar
  87. Linden M. The effects of beta 2-adrenoceptor agonists and a corticosteroids budesonide on the secretion of inflammatory mediators from monocytes. British Journal of Pharmacology 107: 156–160, 1992CrossRefPubMedGoogle Scholar
  88. Lipworth BJ. Risks versus benefits of inhaled β2-agonists in the management of asthma. Drug Safety 7: 54–70, 1992CrossRefPubMedGoogle Scholar
  89. Lipworth BJ, Clark RA, Dhillon DP, McDevitt DG. Subsensitivity of β-adrenoceptor responses in asthmatic patients taking regular low dose inhaled salbutamol. European Journal of Clinical Pharmacology 38: 203–205, 1990CrossRefPubMedGoogle Scholar
  90. Löfdahl CG. Basic pharmacology of new long-acting sympathomimetics. Lung 168 (Suppl.): 18–21, 1990CrossRefPubMedGoogle Scholar
  91. Löfdahl CG, Chung KF. Long-acting beta 2-adrenoceptor agonists: a new perspective in the treatment of asthma. European Respiratory Journal 4: 218–226, 1991PubMedGoogle Scholar
  92. Löfdahl CG, Svedmyr N. Formoterol fumarate, a new beta 2-adrenoceptor agonist: acute studies of selectivity and duration of effect after inhaled and oral administration. Allergy 44: 264–271, 1989CrossRefPubMedGoogle Scholar
  93. Löfdahl CG, Svedmyr N. Beta-agonists: still more friends than foes. European Respiratory Journal 5: 898–900, 1992Google Scholar
  94. Lötvall J, Lunde H, Ullman A, Tornqvist H, Svedmyr N. Twelve months treatment with inhaled salmeterol in asthmatic patients: effects of β2-receptor function and inflammatory cells. Allergy 47: 477–483, 1992CrossRefPubMedGoogle Scholar
  95. Lötvall J, Svedmyr N. Salmeterol: an inhaled β2-agonist with prolonged duration of action. Lung 171: 249–264, 1993CrossRefPubMedGoogle Scholar
  96. Maesen FP, Costongs R, Smeets JJ, Brombacher PJ, Zweers PG. The effect of maximal doses of formoterol and salbutamol from a metered dose inhaler on pulse rates, ECG, and serum potassium concentrations. Chest 99: 1367–1373, 1991CrossRefPubMedGoogle Scholar
  97. Maesen F, Costongs R, Smeets SJ, Zweers PG, Goedhart DM. Formoterol as dry powder inhalation: a dose-finding study in comparison with formoterol metered dose inhaler and placebo. Chest 101: 1376–1381, 1992CrossRefPubMedGoogle Scholar
  98. Maesen FP, Nakratzas G, Bantje TA, Prins J, Zweers PG. Formoterol suspension aerosol: comparison with formoterol solution aerosol for 12 weeks in asthmatic patients. Chest 102: 1544–1549, 1992CrossRefPubMedGoogle Scholar
  99. Maesen FP, Smeets JJ, Gubbelmans HL, Zweers PG. Bronchodilator effect of inhaled formoterol vs salbutamol over 12 hours. Chest 97: 590–594, 1990aCrossRefPubMedGoogle Scholar
  100. Maesen FP, Smeets JJ, Gubbelmans HL, Zweers PG. Formoterol in the treatment of nocturnal asthma. Chest 98: 866–870, 1990bCrossRefPubMedGoogle Scholar
  101. Malo JL, Cartier A, Trudeau C, Ghezzo H, Gontovnick L. Formoterol, a new inhaled beta-2 adrenergic agonist, has a longer blocking effect than albuterol on hyperventilation-induced bronchoconstriction. American Review of Respiratory Disease 142: 1147–1152, 1990PubMedGoogle Scholar
  102. Malo JL, Ghezzo H, Trudeau C, L’Archevêque J, Cartier A. Salmeterol, a new inhaled beta 2-adrenergic agonist, has a longer blocking effect than albuterol on hyperventilation-induced bronchoconstriction. Journal of Allergy and Clinical Immunology 89: 567–574, 1992CrossRefPubMedGoogle Scholar
  103. McAlpine LG, Thomson NC. Prophylaxis of exercise-induced asthma with inhaled formoterol, a long-acting beta-2 adrenergic agonist. Respiratory Medicine 84: 293–295, 1990CrossRefPubMedGoogle Scholar
  104. Midgren B, Melander B, Persson G. Formoterol, a new long-acting beta 2 agonist, inhaled twice daily, in stable asthmatic subjects. Chest 101: 1019–1022, 1992CrossRefPubMedGoogle Scholar
  105. Mitchell EA. Is current treatment increasing asthma mortality and morbidity?. Thorax 44: 81–84, 1989CrossRefPubMedGoogle Scholar
  106. Molfino NA, Nannini LJ, Martelli AN, Slutsky AS. Respiratory arrest in near-fatal asthma. New England Journal of Medicine 324: 285–288, 1991CrossRefPubMedGoogle Scholar
  107. Morgan DJ. Clinical pharmacokinetics of β-agonists. Clinical Pharmacokinetics 18: 270–294, 1990CrossRefPubMedGoogle Scholar
  108. Morice AH. A European respiratory review on salmeterol. European Respiratory Journal 4: 1166–1167, 1991PubMedGoogle Scholar
  109. Muir JF, Bertin L, Georges D (French Multicentre Study Group). Salmeterol versus slow-release theophylline combined with ketotifen in nocturnal asthma: a multicentre trial. European Respiratory Journal 5: 1197–1200, 1992PubMedGoogle Scholar
  110. National Asthma Education Program. Guidelines for the diagnosis and management of asthma, US Department of Health and Human Services, NIH, 1991Google Scholar
  111. Nelson HS, Szefler SJ, Martin RJ. Regular inhaled beta-adrenergic agonists in the treatment of bronchial asthma: beneficial or detrimental?. American Review of Respiratory Disease 144: 249–250, 1991CrossRefPubMedGoogle Scholar
  112. Nials AT, Sumner MJ, Johnson M, Coleman RA. Investigations into factors determining the duration of action of the beta 2-adrenoceptor agonist, salmeterol. British Journal of Pharmacology 108: 507–515, 1993CrossRefPubMedGoogle Scholar
  113. Nicklas RA, Whitehurst VE, Donohoe RF, Balacz T. Concomitant use of beta adrenergic agonists and methylxanthines. Journal of Allergy and Clinical Immunology 73: 20–24, 1984CrossRefPubMedGoogle Scholar
  114. Nijkamp FP, Engels F, Henricks PAJ, van Oosterhout AJM. Mechanisms of β-adrenergic receptor regulation in lung and its implication for physiological responses. Physiological Review 72: 323–367, 1992Google Scholar
  115. Nix A, Nichol GM, Robson A, Barnes PJ, Chung KF. Effect of formoterol, a long-lasting beta 2-adrenoceptor agonist, against methacholine-induced bronchoconstriction. British Journal of Clinical Pharmacology 29: 321–324, 1990CrossRefPubMedGoogle Scholar
  116. Nowak D, Jorres R, Rabe KF, Luthke M, Wiessmann J, et al. Salmeterol protects against hyperventilation-induced bronchoconstriction over 12 hours. European Journal of Clinical Pharmacology 43: 591–596, 1992CrossRefPubMedGoogle Scholar
  117. O’Byrne PM, Dolovich J, Hargreave FE. Late asthmatic responses. American Review of Respiratory Disease 136: 740–751, 1987CrossRefPubMedGoogle Scholar
  118. O’Byrne PM, Morris M, Roberts R, Hargreave FE. Inhibition of the bronchial response to respiratory heat exchange by increasing doses of terbutaline sulphate. Thorax 37: 913–917, 1982CrossRefPubMedGoogle Scholar
  119. O’Connor BJ, Aikman SL, Barnes PJ. Tolerance to bronchodilator effects of inhaled β2-agonists in asthma. New England Journal of Medicine 327: 1204–1208, 1992CrossRefPubMedGoogle Scholar
  120. O’Donnell TV, Rea HH, Holst PE, Sears MR. Fenoterol and fatal asthma. Correspondence. Lancet 1: 1070–1071, 1989CrossRefGoogle Scholar
  121. Page CP. One explanation of the asthma paradox: inhibition of natural anti-inflammatory mechanisms by beta-2-agonists. Lancet 337: 717–720, 1991CrossRefPubMedGoogle Scholar
  122. Page CP. Beta agonists and the asthma paradox. Journal of Asthma 30: 155–164, 1993CrossRefPubMedGoogle Scholar
  123. Page C, Costello J. Why β-agonists should not be used regularly. Respiratory Medicine 86: 477–479, 1992CrossRefPubMedGoogle Scholar
  124. Palmer JB, Stuart AM, Shepherd GL, Viskum K. Inhaled salmeterol in the treatment of patients with moderate to severe reversible obstruction airways disease, a 3 month comparison of the efficacy and safety of twice-daily salmeterol (100 micrograms) with salmeterol (50 micrograms). Respiratory Medicine 86: 409–417, 1992CrossRefPubMedGoogle Scholar
  125. Palmqvist M, Balder B, Lowhage O, Melander B, Svedmyr N, et al. Late asthmatic reaction decreased after pretreatment with salbutamol and formoterol, a new long-acting beta 2-agonist. Journal of Allergy and Clinical Immunology 89: 844–849, 1992CrossRefPubMedGoogle Scholar
  126. Patakas KBJ, Maniki E, Tsara V, Daskalopoulou E. Intermittent and continous salbutamol rotacaps inhalation in asthmatic patients. Respiratory Medicine 54: 174–178, 1988Google Scholar
  127. Patessio A, Podda A, Carone M, Trombetta N, Donner CF. Protective effect and duration of action of formoterol aerosol on exercise-induced asthma. European Respiratory Journal 4: 296–300, 1991PubMedGoogle Scholar
  128. Pauwels R, Derom E, van der Straeten M. Onset of action of beta-2-agonists by comparison of inhaled formoterol vs inhaled salbutamol. Abstract. European Respiratory Journal 2: 652S, 1989Google Scholar
  129. Pearce N, Crane J, Burgess C, Jackson R, Beasley R. Beta-agonists and asthma mortality: déjà vu. Clinical and Experimental Allergy 21: 401–410, 1991CrossRefPubMedGoogle Scholar
  130. Pearce NE, Grainger J, Atkinson M, Crane J, Burgess C, et al. Casecontrol study of prescribed fenoterol and death from asthma in New Zealand 1977-1981. Thorax 45: 170–175, 1990CrossRefPubMedGoogle Scholar
  131. Pearlman DS, Chervinsky P, LaForce C, Seltzer JM, Southern DL, et al. A comparison of salmeterol with albuterol in the treatment of mild to moderate asthma. New England Journal of Medicine 327: 1420–1425, 1992CrossRefPubMedGoogle Scholar
  132. Pedersen B, Dahl R, Larsen BB, Venge P. The effect of salmeterol on the early- and late-phase reaction to bronchial allergen and postchallenge variation in bronchial reactivity, blood eosinophils, serum eosinophil cationic protein and serum eosinophil protein X. Allergy 48: 377–382, 1993CrossRefPubMedGoogle Scholar
  133. Petty TL, Brandon ML, Busse WW, Chervinsky P, Schoenweter W, et al. A comparison of oral procaterol an albuterol in reversible airflow obstruction. American Review of Respiratory Disease 138: 1504–1509, 1988PubMedGoogle Scholar
  134. Poole C, Lanes SF, Walker AM. Fenoterol and fatal asthma. Correspondence. Lancet 1: 920, 1990CrossRefGoogle Scholar
  135. Qallin A, Melander B, Rosenhall L, Sandström T, Wohlander L. Formoterol a new long-acting β-2 agonist for inhalation twice daily compared with salbutamol in the treatment of asthma. Thorax 45: 259–261, 1990CrossRefGoogle Scholar
  136. Rabe KF, Chung KF. The challenge of long-acting beta-adrenoceptor agonists. Respiratory Medicine 85: 5–9, 1991CrossRefPubMedGoogle Scholar
  137. Rabe KF, Jörres R, Nowak D, Behr N, Magnussen H. Comparison of the effects of salmeterol and formoterol on airway tone and responsiveness over 24 hours in bronchial asthma. American Review of Respiratory Disease 147: 1436–1441, 1993PubMedGoogle Scholar
  138. Ramsdale EH, Otis J, Kline PA, Gontovnick LS, Hargreave FE, et al. Prolonged protection against methacholine-induced broncho-constriction by the inhaled β-2 agonist formoterol. American Review of Respiratory Disease 143: 998–1001, 1991PubMedGoogle Scholar
  139. Rees J. Beta 2 agonists and asthma. British Medical Journal 302: 1166–1167, 1991CrossRefPubMedGoogle Scholar
  140. Repsher LH, Anderson JA, Bush RK, Falliers CJ, Kass I, et al. Assessment of tachyphylaxis following prolonged therapy with inhaled albuterol aerosol. Chest 85; 34–38, 1984CrossRefPubMedGoogle Scholar
  141. Roberts JA, Bradding P, Wallis AF, Britten KM, Wilson S, et al. The influence of salmeterol xinafoate on mucosal inflammation in asthma. American Review of Respiratory Disease 145: A418, 1992Google Scholar
  142. Robin ED, McCauley R. Sudden cardiac death in bronchial asthma, and inhaled beta-adrenergic agonists. Chest 101: 1699–1702, 1992CrossRefPubMedGoogle Scholar
  143. Rona G. Cathecholamine cardiotoxicity. Journal of Molecular and Cellular Cardiology 17: 291, 1985CrossRefPubMedGoogle Scholar
  144. Schultze-Werninghaus G. Multicenter 1-year trial on formoterol, a new long-acting beta 2-agonist, in chronic obstructive airway disease. Lung 168 (Suppl.): 83–89, 1990CrossRefPubMedGoogle Scholar
  145. Sears MR, Taylor DR, Print CG, Lake DC, Li Q, et al. Regular inhaled β-agonist treatment in bronchial asthma. Lancet 336: 1391–1396, 1990CrossRefPubMedGoogle Scholar
  146. Shepherd GI, Getzel MR, Clark TJH. Regular versus symptomatic aerosol bronchodilator treatment of asthma. British Journal of Diseases of the Chest 75: 215–217, 1981CrossRefPubMedGoogle Scholar
  147. Shepherd GL, Jenkins WJ, Alexander J. Asthma exacerbations in patients taking regular salmeterol, or salbutamol for symptoms. Lancet 337: 1424–1428, 1991CrossRefPubMedGoogle Scholar
  148. Shima K, Takenaka S. The clinical evaluation of formoterol (BD 40A) in bronchial asthma with long term administration and in chronic obstructive pulmonary disease with short term administration. Yakuri to Chiryo 11: 3935–3942, 1983Google Scholar
  149. Silverglade A. Asthma deaths and bronchodilator aerosols. American Review of Respiratory Disease 107: 1076–1078, 1973PubMedGoogle Scholar
  150. Simons FE, Soni NR, Watson WT, Becker AB. Bronchodilator and bronchoprotective effects of salmeterol in young patients with asthma. Journal of Allergy and Clinical Immunology 90: 840–846, 1992CrossRefPubMedGoogle Scholar
  151. Skorodin MS. Beta-adrenergic agonists: a problem. Chest 5: 1587–1590, 1993CrossRefGoogle Scholar
  152. Smyth ET, Pavord ID, Wong CS, Wisniewski AF, Williams J, et al. Interaction and dose equivalence of salbutamol and salmeterol in patients with asthma. British Medical Journal 306: 543–545, 1993CrossRefPubMedGoogle Scholar
  153. Solis-Cohen S. The use of adrenal substances in the treatment of asthma. Journal of the American Medical Association 34: 1164–1166, 1900CrossRefGoogle Scholar
  154. Sovijarvi AR, Reinikainen K, Freudenthal Y, Andersson P, Riska H. Preventive effects of inhaled formoterol and salbutamol on histamine-induced bronchoconstriction: a placebo controlled study. Respiration 59: 279–282, 1992CrossRefPubMedGoogle Scholar
  155. Spitzer WO, Suissa S, Ernst P, Horwitz RI, Hobbick B, et al. The use of β-agonists and the risk of death and near death from asthma. New England Journal of Medicine 326: 501–506, 1992CrossRefPubMedGoogle Scholar
  156. Spring J, Johnston SR, Seale J, Ind PW. Failure of salmeterol to inhibit circulating white cell responses and bronchoconstriction induced by platelet activating factor. Thorax 47: 948–951, 1992CrossRefPubMedGoogle Scholar
  157. Stam J, Souren M, Zweers P. The onset of action of formoterol, a new beta 2 adrenoceptor agonist. International Journal of Clinical Pharmacology and Therapy and Toxicology 31: 23–26, 1993Google Scholar
  158. Staudinger HW, Hass JE Beta-agonists: friends or foes?. European Respiratory Journal 5: 894–896, 1992PubMedGoogle Scholar
  159. Suissa S, Ernst P, Biais L, Spitzer W. Increasing patterns of β-agonist use and the risk of fatal or near-fatal asthma. Proceedings of the 9th International Conference on Pharmacoepidemiology, p.2, Aug–Sept, 1992Google Scholar
  160. Svedmyr N, Löfdahl CG. Physiology and pharmacodynamics of beta-adrenergic agonists. In Jenner & Murphy (Eds) Drug therapy for asthma: research and clinical practice, pp. 177–211, Marcel Dekker, New York, 1987Google Scholar
  161. Tattersfield AE. Long-acting beta 2-agonists. Clinical and Experimental Allergy 22: 600–605, 1992CrossRefPubMedGoogle Scholar
  162. Tattersfield AE. Effect of β-agonists and anticholinergic drugs on bronchial reactivity. American Review of Respiratory Disease 136 (Suppl.): S64–S68, 1987PubMedGoogle Scholar
  163. Taylor DR, Sears MR, Herbison GP, Flannery EM, Print CG, et al. Regular inhaled β agonist in asthma: effects on exacerbations and lung function. Thorax 48: 134–138, 1992CrossRefGoogle Scholar
  164. Taylor IK, O’Shaughnessy KM, Choudry NB, Adachi M, Palmer JB, et al. A comparative study in atopic subjects with asthma of the effects of salmeterol and salbutamol on allergen-induced bronchoconstriction, increase in airway reactivity, and increase in urinary leukotriene E4 excretion. Journal of Allergy and Clinical Immunology 89: 575–583, 1992CrossRefPubMedGoogle Scholar
  165. Tokuyama K, Lotvall JO, Lofdahl CG, Barnes PJ, Chung KF. Inhaled formoterol inhibits histamine-induced airflow obstruction and airway microvascular leakage. European Journal of Pharmacology 193: 35–40, 1991CrossRefPubMedGoogle Scholar
  166. Trembath PW, Greenacre JK, Anderson M, Dimmock S, Mansfield L, et al. Comparison for four weeks’ treatment with fenoterol and terbutaline aerosols in adult asthmatics: a double-blind crossover study. Journal of Allergy and Clinical Immunology 63: 395–400, 1979CrossRefPubMedGoogle Scholar
  167. Twentyman OP, Finnerty JP, Harris A, Palmer J, Holgate ST. Protection against allergen-induced asthma by salmeterol. Lancet 336: 1338–1342, 1990CrossRefPubMedGoogle Scholar
  168. Twentyman OP, Finnerty JP, Holgate ST. The inhibitory effect of nebulized albuterol on the early and late asthmatic reactions and increase in airway responsiveness provoked by inhaled allergen in asthma. American Review of Respiratory Disease 144: 782–787, 1991CrossRefPubMedGoogle Scholar
  169. Ullman A, Bergendal A, Linden A, Waldeck B, Skoogh BE, et al. Onset of action and duration of effect of formoterol and salmeterol compared to salbutamol in isolated guinea pig trachea with or without epithelium. Allergy 47: 384–387, 1992CrossRefPubMedGoogle Scholar
  170. Ullman A, Hedner J, Svedmyr N. Inhaled salmeterol and salbutamol in asthmatic patients: an evaluation of asthma symptoms and the possible development of tachyphy Iaxis. American Review of Respiratory Disease 142: 571–575, 1990CrossRefPubMedGoogle Scholar
  171. Ullman A, Svedmyr N. Salmeterol, a new long acting β2 ad-renoreceptor agonist: a comparison with salbutamol in adult asthmatic patients. Thorax 43: 674–678, 1988CrossRefPubMedGoogle Scholar
  172. Van Arsdel PP, Schaffrin RM, Rosenblatt J, Sprenkle AC, Altman LC. Evaluation of oral fenoterol in chronic asthmatic patients. Chest 73: 997–998, 1978Google Scholar
  173. Vandewalker ML, Dray K, Weber RW, Nelson HS. Addition of terbutaline to optimal theophylline therapy: double-blind crossover study in asthmatic patients. Chest 90: 198–205, 1986CrossRefPubMedGoogle Scholar
  174. van Schayck CP, Graafsma SJ, Visch MB, Dompeling E, van Weel C, et al. Increased bronchial hyperresponsiveness after inhaling salbutamol during 1 year is not caused by subsensitization to salbutamol. Journal of Allergy and Clinical Immunology 86: 793–800, 1990CrossRefPubMedGoogle Scholar
  175. Vathenen AS, Knox AJ, Higgins BG, Britton JR, Tattersfield AE. Rebound increase in bronchial responsiveness after treatment with inhaled terbutaline. Lancet 1: 554–558, 1988CrossRefPubMedGoogle Scholar
  176. Verberne AA, Hop WC, Bos AB, Kerrebijn KE. Effect of a single dose of inhaled salmeterol on baseline airway caliber and methacholine-induced airway obstruction in asthmatic children. Journal of Allergy and Clinical Immunology 91: 127–134, 1993CrossRefPubMedGoogle Scholar
  177. von Berg A, Berdel D. Formoterol and salbutamol metered aerosols: comparison of a new and an established beta-2 agonist for their bronchodilating efficacy in the treatment of childhood bronchial asthma. Pediatric Pulmonology 7: 89–93, 1989CrossRefGoogle Scholar
  178. von Berg A, Berdel D. Efficacy of formoterol metered aerosol in children. Lung 168 (Suppl.): 90–98. 1990CrossRefGoogle Scholar
  179. Wahedna I, Wong CS, Wisniewski AFZ, Pavord ID, Tattersfield AE. Asthma control during and after cessation of regular beta2 agonist treatment. American Review of Respiratory Disease 148: 707–712, 1993CrossRefPubMedGoogle Scholar
  180. Wallin A, Melander B, Rosenhall L, Sandstrom T, Wahlander L. Formoterol, a new long-acting beta-2 agonist for inhalation twice daily, compared with salbutamol in the treatment of asthma. Thorax 45: 259–261, 1990CrossRefPubMedGoogle Scholar
  181. Weber RW, Smith JA, Nelson HS. Aerosolized terbutaline in asthmatics: development of subsensitivity with long-term administration. Journal of Allergy and Clinical Immunology 70: 417–423, 1982CrossRefPubMedGoogle Scholar
  182. Weersink EJM, Aalbers R, Koëter GH, Kauffman HF, de Monchy JGR. Salmeterol, inhibiting or masking the late asthmatic reaction after HDM challenge. American Review of Respiratory Disease 147 (Suppl.): A25, 1993CrossRefGoogle Scholar
  183. Wegener T, Hedenstrom H, Melander B. Rapid onset of action of inhaled formoterol in asthmatic patients. Chest 102:535–538,1992CrossRefPubMedGoogle Scholar
  184. Whelan CJ, Johnson M. Inhibition by salmeterol of increased vascular permeability and granulocyte accumulation in guinea-pig lung and skin. British Journal of Pharmacology 105: 831–838, 1992CrossRefPubMedGoogle Scholar
  185. Wilkinson JR, Roberts JA, Bradding P, Holgate ST, Howarth PH. Paradoxical bronchoconstriction in asthmatic patients after salmeterol by metered dose inhaler. British Medical Journal 305: 931–932, 1992CrossRefPubMedGoogle Scholar
  186. Wong BJ, Dolovich J, Ramsdale EH, O’Byrne P, Gontovnick L, et al. Formoterol compared with beclomethasone and placebo on allergen-induced asthmatic responses. American Review of Respiratory Disease 146: 1156–1160, 1992PubMedGoogle Scholar
  187. Ziment I. Beta-adrenergic agonist toxicity: less of a problem, more of a perception. Chest 5: 1591–1597, 1993CrossRefGoogle Scholar

Copyright information

© Adis International Limited 1994

Authors and Affiliations

  • Louis-Philippe Boulet
    • 1
  1. 1.Centre de Pneumologie de l’Hôpital LavalUniversité LavalSainte-FoyCanada

Personalised recommendations